Senseonics Raises 2026 Revenue Guidance to $68 Million to $70 Million

Senseonics Holdings, Inc. raised its 2026 global revenue guidance to $68 million to $70 million after quarterly revenue rose 140% and its Freedom system entered human testing in October.

The previous guidance range was $62 million to $66 million. The new range represents 93% to 98% year-over-year growth.

Revenue for the third quarter totaled $19.6 million, up from $8.1 million a year earlier. Gross margin was about 62%. Senseonics raised its full-year gross-margin outlook to above 60%, from a previous range of 58% to 61%.

Senseonics began a first-in-human study of Freedom on Oct. 26. The investigational continuous glucose monitoring (CGM) system is designed to connect with a mobile device without hardware worn on the body. The study is assessing safety, device operation and Bluetooth communication.

Senseonics expects to begin a pivotal study in 2027 and is targeting a potential commercial launch in 2028.